WSO - February 2024 - 202

202
International Journal of Stroke 19(2)
Figure 1. Design and flow of participants through the trial.
characteristics between participants retained and lost to
follow-up at 12 months.
One intervention therapist (physiotherapist, 15 years'
experience) provided the majority (334 (63%) of PA intervention
sessions. The remainder were provided by another
physiotherapist (20 years' experience), and an exercise scientist
(28 years' experience). All DIET intervention sessions
were provided by the same dietitian (5 years'
experience).
Feasibility
Between March 2020 and January 2022, we screened 99
people: 45 were ineligible, 14 declined, and 40 were
randomized (Figure 1). The most common reason for ineligibility
was being too physically active (n = 31). Six participants
withdrew from the trial, and an additional 5
participants were lost to follow-up (Figure 1). The proportion
of missing data for the clinical outcome of blood
pressure was 3% at 3 months, 11% at 6 months, and 14%
at 12 months (Table 2).
A total of 527 (73% of scheduled) PA sessions were
attended. During supervised exercise sessions, participants,
on average, exercised for 20 (SD 0.4) minutes,
International Journal of Stroke, 19(2)
reached 65% (SD 7) of their predicted HRmax, and had a
perceived exertion rating of 3.4 (SD 1.0) on the Borg CR-10
scale (Table 2). A total of 182 (91% of scheduled) diet sessions
were attended.
Safety
Fifteen serious adverse events occurred (mostly hospitalization
for unrelated health issues); none were deemed definitely
or probably related to the trial. There were 85 adverse
events; 25 were deemed possibly or probably related, and 5
(light-headedness, pain) were deemed definitely related to
the intervention. No falls occurred during supervised exercise
sessions. See Supplemental Tables.
Effect of the PA intervention on stroke risk
factors, fatigue, mood, and quality of life
Table 3 presents results for the effect of the PA intervention
on stroke risk factors, fatigue, mood, and quality of life.
There were no significant differences for changes in blood
pressure over time. There was, however, a trend toward
greater systolic and diastolic blood pressure reductions at
3 months in the PA group compared with CONTROL (mean

WSO - February 2024

Table of Contents for the Digital Edition of WSO - February 2024

Contents
WSO - February 2024 - Cover1
WSO - February 2024 - Cover2
WSO - February 2024 - 127
WSO - February 2024 - Contents
WSO - February 2024 - 129
WSO - February 2024 - 130
WSO - February 2024 - 131
WSO - February 2024 - 132
WSO - February 2024 - 133
WSO - February 2024 - 134
WSO - February 2024 - 135
WSO - February 2024 - 136
WSO - February 2024 - 137
WSO - February 2024 - 138
WSO - February 2024 - 139
WSO - February 2024 - 140
WSO - February 2024 - 141
WSO - February 2024 - 142
WSO - February 2024 - 143
WSO - February 2024 - 144
WSO - February 2024 - 145
WSO - February 2024 - 146
WSO - February 2024 - 147
WSO - February 2024 - 148
WSO - February 2024 - 149
WSO - February 2024 - 150
WSO - February 2024 - 151
WSO - February 2024 - 152
WSO - February 2024 - 153
WSO - February 2024 - 154
WSO - February 2024 - 155
WSO - February 2024 - 156
WSO - February 2024 - 157
WSO - February 2024 - 158
WSO - February 2024 - 159
WSO - February 2024 - 160
WSO - February 2024 - 161
WSO - February 2024 - 162
WSO - February 2024 - 163
WSO - February 2024 - 164
WSO - February 2024 - 165
WSO - February 2024 - 166
WSO - February 2024 - 167
WSO - February 2024 - 168
WSO - February 2024 - 169
WSO - February 2024 - 170
WSO - February 2024 - 171
WSO - February 2024 - 172
WSO - February 2024 - 173
WSO - February 2024 - 174
WSO - February 2024 - 175
WSO - February 2024 - 176
WSO - February 2024 - 177
WSO - February 2024 - 178
WSO - February 2024 - 179
WSO - February 2024 - 180
WSO - February 2024 - 181
WSO - February 2024 - 182
WSO - February 2024 - 183
WSO - February 2024 - 184
WSO - February 2024 - 185
WSO - February 2024 - 186
WSO - February 2024 - 187
WSO - February 2024 - 188
WSO - February 2024 - 189
WSO - February 2024 - 190
WSO - February 2024 - 191
WSO - February 2024 - 192
WSO - February 2024 - 193
WSO - February 2024 - 194
WSO - February 2024 - 195
WSO - February 2024 - 196
WSO - February 2024 - 197
WSO - February 2024 - 198
WSO - February 2024 - 199
WSO - February 2024 - 200
WSO - February 2024 - 201
WSO - February 2024 - 202
WSO - February 2024 - 203
WSO - February 2024 - 204
WSO - February 2024 - 205
WSO - February 2024 - 206
WSO - February 2024 - 207
WSO - February 2024 - 208
WSO - February 2024 - 209
WSO - February 2024 - 210
WSO - February 2024 - 211
WSO - February 2024 - 212
WSO - February 2024 - 213
WSO - February 2024 - 214
WSO - February 2024 - 215
WSO - February 2024 - 216
WSO - February 2024 - 217
WSO - February 2024 - 218
WSO - February 2024 - 219
WSO - February 2024 - 220
WSO - February 2024 - 221
WSO - February 2024 - 222
WSO - February 2024 - 223
WSO - February 2024 - 224
WSO - February 2024 - 225
WSO - February 2024 - 226
WSO - February 2024 - 227
WSO - February 2024 - 228
WSO - February 2024 - 229
WSO - February 2024 - 230
WSO - February 2024 - 231
WSO - February 2024 - 232
WSO - February 2024 - 233
WSO - February 2024 - 234
WSO - February 2024 - 235
WSO - February 2024 - 236
WSO - February 2024 - 237
WSO - February 2024 - 238
WSO - February 2024 - 239
WSO - February 2024 - 240
WSO - February 2024 - 241
WSO - February 2024 - 242
WSO - February 2024 - 243
WSO - February 2024 - 244
WSO - February 2024 - Cover3
WSO - February 2024 - Cover4
https://europe.nxtbook.com/nxteu/sageuk/wso_202404
https://europe.nxtbook.com/nxteu/sageuk/ukstrokeforum_202402_supp
https://europe.nxtbook.com/nxteu/sageuk/wso_202403
https://europe.nxtbook.com/nxteu/sageuk/wso_202402
https://europe.nxtbook.com/nxteu/sageuk/wso_202401
https://europe.nxtbook.com/nxteu/sageuk/wso_2023123_US_UKOnly
https://europe.nxtbook.com/nxteu/sageuk/wso_2023123_ROW
https://europe.nxtbook.com/nxteu/sageuk/wso_2023101
https://europe.nxtbook.com/nxteu/sageuk/wso_202308
https://europe.nxtbook.com/nxteu/sageuk/wso_202307
https://europe.nxtbook.com/nxteu/sageuk/wso_202306
https://europe.nxtbook.com/nxteu/sageuk/wso_202304
https://europe.nxtbook.com/nxteu/sageuk/wso_202303
https://europe.nxtbook.com/nxteu/sageuk/wso_202302
https://europe.nxtbook.com/nxteu/sageuk/wso_202301
https://www.nxtbookmedia.com